Ablynx said that this is the first lead candidate emerging from the Alzheimer’s disease collaboration between Ablynx and Boehringer Ingelheim and is expected to result in a EUR2m milestone payment to Ablynx.
Boehringer Ingelheim and Ablynx have entered into a research and licensing agreement in January 2007 to discover and develop new therapies for Alzheimer’s disease using Ablynx’s nanobodies, worth a possible $265m in milestone payments plus undisclosed royalties.
Boehringer Ingelheim will be responsible for the development, manufacture and commercialisation of any products resulting from the research collaboration.
Edwin Moses, CEO and chairman of Ablynx, said: “Ablynx’s delivery of this Nanobody candidate for the treatment of Alzheimer’s disease represents the speed at which we progressed from initiation of the discovery programme in 2007 to this stage of development.”